Today: 9 June 2026
Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention
2 January 2026
2 mins read

Broadcom stock today: AVGO holds gains after hours as CFO sale notice and chip rally grab attention

NEW YORK, Jan 2, 2026, 17:03 ET — After-hours

  • Broadcom shares rose 0.4% to $347.62 in the regular session and were little changed after hours.
  • A U.S. filing showed CFO Kirsten M. Spears plans to sell up to 30,000 shares.
  • Chip stocks led a broad rebound; traders are watching next week’s U.S. jobs data and Broadcom’s next earnings.

Broadcom Inc. shares rose 0.4% to $347.62 on Friday and were little changed in after-hours trading, after swinging between $345.61 and $360.56. About 24.8 million shares changed hands, according to market data.

The stock held steady late in the day as investors digested a disclosure pointing to a potential share sale by Broadcom’s finance chief, and as chip stocks rebounded to start 2026.

That matters now because Broadcom sits at the center of the market’s “AI infrastructure” trade — the semiconductor and networking plumbing that supports large-scale data centers — while its VMware software business gives it a second engine that some investors view as more predictable.

Small insider-sale notices can still draw attention in mega-cap names, where positioning has become crowded and valuations have been sensitive to any shift in risk appetite.

In a Form 144 filed on Dec. 31, CFO Kirsten M. Spears reported an intent to sell up to 30,000 Broadcom shares, with an aggregate market value of about $10.43 million. A Form 144 is a notice corporate insiders file with U.S. regulators ahead of a potential sale of restricted or control stock; the filing listed about 4.74 billion shares outstanding.

Broadcom’s modest gain came as chipmakers helped lift the broader market. The Dow and S&P 500 ended higher, and the Philadelphia Semiconductor Index — a benchmark for major chip stocks — jumped about 4% as names such as Nvidia and Intel advanced. “Investors might be a little bit more conscious about some of the valuations that they’re paying for some of the AI plays,” said Joe Mazzola, head of trading and derivatives strategist at Charles Schwab. Reuters

Broadcom also used Friday to sharpen its messaging around VMware in Europe, the Middle East and Africa. In a company post, a Broadcom executive described a push toward a smaller, more “capable” partner ecosystem to support VMware Cloud Foundation deployments, citing tighter regulation and customer focus on cost and resilience. Broadcom News and Stories

The VMware integration remains a key watchpoint for investors because Broadcom has been leaning on software to smooth the lumpier swings typical in semiconductors, while still pitching AI-driven growth in custom chips and data-center networking.

In its most recent quarterly release in December, Broadcom forecast first-quarter fiscal 2026 revenue of about $19.1 billion and adjusted EBITDA of about 67% of sales, underscoring how strongly it expects demand to carry into early 2026.

Next up, traders will focus on next week’s U.S. labor market data, which markets often treat as a key input for the Federal Reserve’s interest-rate path. Broadcom’s next earnings are scheduled for March 4, based on Yahoo Finance’s earnings calendar, setting up the next major catalyst for guidance around AI networking demand and software performance.

For near-term traders, Friday’s intraday high near $361 and low around $346 are the closest markers after a session that reversed from an opening pop. A retest of $360 would put recent highs back in view, while a break below $345 would signal that sellers are regaining control.

The early-2026 setup leaves Broadcom in the crosshairs of two forces: a chip-sector rebound that can move the whole group at once, and a market that is increasingly price-sensitive around AI-linked valuations.

Stock Market Today

  • NOV Stock Up 32% in Six Months: Key Factors and Investor Outlook
    June 9, 2026, 10:21 AM EDT. NOV Inc. shares have surged 31.5% over six months, outpacing the Mechanical and Equipment Oil and Gas sub-industry and broader energy sector. The company benefits from strong offshore equipment demand, driven by subsea flexible pipe growth and offshore projects through 2028. NOV's focus on automation and cost reduction, including headcount and facility cuts, supports operational efficiency. Management anticipates a multi-year upcycle in capital equipment spending due to energy security and renewed offshore investment, bolstering demand. With a solid backlog and positive 2026 earnings outlook, NOV's positioning suggests potential for continued gains, raising questions for investors on whether to hold or sell amid market shifts.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Caterpillar stock jumps 4% as Wolfe lifts target to $670; investors brace for Jan. 9 jobs report
Previous Story

Caterpillar stock jumps 4% as Wolfe lifts target to $670; investors brace for Jan. 9 jobs report

Shopify stock slides after Canadian court order in CRA data dispute
Next Story

Shopify stock slides after Canadian court order in CRA data dispute

Go toTop